Grossenbrode, Germany

Timo Gemoll

This inventor holds 1 USPTO granted patent and 1 published patent application and 3 EPO patents. Top assignee: Neoproteomics Ab. Active years: 2018.

USPTO Granted Patents = 1 

% Patents Active = 100.0

 

Average Co-Inventor Count = 6.0

ph-index = 1


Company Filing History:


Years Active: 2018

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Timo Gemoll: Innovator in Cancer Diagnostics

Introduction

Timo Gemoll is a notable inventor based in Grossenbrode, Germany. He has made significant contributions to the field of cancer diagnostics, particularly through his innovative research and patents. His work focuses on the use of platelet-derived biomarkers for diagnosing cancer and assessing cancer progression.

Latest Patents

Timo Gemoll holds a patent titled "Platelet biomarkers in cancer diagnosis." This patent relates to the field of cancer diagnostics and emphasizes the importance of platelet-derived biomarkers in diagnosing cancer, determining cancer progression, and improving treatment outcomes. He has 1 patent to his name, showcasing his commitment to advancing medical science.

Career Highlights

Throughout his career, Timo has worked with reputable organizations, including Neoproteomics AB and the University of Lübeck. His experience in these institutions has allowed him to collaborate with other experts in the field and contribute to groundbreaking research in cancer diagnostics.

Collaborations

Timo has collaborated with notable colleagues such as Susanne Becker and Jens Habermann. These partnerships have enriched his research and expanded the impact of his work in the scientific community.

Conclusion

Timo Gemoll's contributions to cancer diagnostics through his innovative patent and collaborations highlight his role as a key figure in the field. His work continues to influence the development of effective diagnostic tools for cancer, ultimately benefiting patient care and treatment.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…